



C4X Discovery

A new dimension in drug discovery

C4X Discovery enters collaboration with Evotec AG

Manchester and London, UK, 8 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has signed a research collaboration agreement under which C4XD's proprietary NMR-based technology will be applied across a number of Evotec's pre-clinical therapeutic projects to enhance lead discovery and hit identification.

C4XD has the only technology in the world that can generate accurate, experimentally-derived 3D structures of drug molecules in just a matter of days. It can be used in conjunction with existing technologies for structure-based design such as X-ray co-crystallography. Equally, it can also be used when crystallography is unavailable, as is the case for certain GPCRs and ion channels.

Piers Morgan, CEO of C4X, said "We are delighted to partner with Evotec, a global leader in high-quality drug discovery solutions. This collaboration will provide increased visibility of the potential advantages and benefits of C4XD's technology."

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are pleased to partner with C4XD and are excited about the potential of this alliance. C4XD has a highly innovative platform technology which complements our strong research base to accelerate product development."

--ENDS--

For further information please contact:

C4X Discovery Ltd

Piers Morgan, CEO

07912 293832

Ben Atwell / John Dineen, FTI

020 3727 1136

comms@c4xdiscovery.com

About C4X Discovery Ltd

C4X Discovery is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4X Discovery's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4X Discovery is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. It has been funded since inception by life science investor Aquarius Equity Partners. www.c4xdiscovery.com

About Evotec

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Hyperion Therapeutics in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.